Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Infection of Primary Human Alveolar Macrophages Alters Staphylococcus aureus Toxin Production and Activity.

Brann KR, Fullerton MS, Onyilagha FI, Prince AA, Kurten RC, Rom JS, Blevins JS, Smeltzer MS, Voth DE.

Infect Immun. 2019 Jun 20;87(7). pii: e00167-19. doi: 10.1128/IAI.00167-19. Print 2019 Jul.

PMID:
31010814
2.

Comparative Study of Antibiotic Elution Profiles From Alternative Formulations of Polymethylmethacrylate Bone Cement.

Meeker DG, Cooper KB, Renard RL, Mears SC, Smeltzer MS, Barnes CL.

J Arthroplasty. 2019 Jul;34(7):1458-1461. doi: 10.1016/j.arth.2019.03.008. Epub 2019 Mar 12.

PMID:
30935799
3.

Label-Free Proteomic Approach to Characterize Protease-Dependent and -Independent Effects of sarA Inactivation on the Staphylococcus aureus Exoproteome.

Byrum SD, Loughran AJ, Beenken KE, Orr LM, Storey AJ, Mackintosh SG, Edmondson RD, Tackett AJ, Smeltzer MS.

J Proteome Res. 2018 Oct 5;17(10):3384-3395. doi: 10.1021/acs.jproteome.8b00288. Epub 2018 Sep 27.

4.

Synthesis and antimicrobial studies of hydrazone derivatives of 4-[3-(2,4-difluorophenyl)-4-formyl-1H-pyrazol-1-yl]benzoic acid and 4-[3-(3,4-difluorophenyl)-4-formyl-1H-pyrazol-1-yl]benzoic acid.

Zakeyah AA, Whitt J, Duke C, Gilmore DF, Meeker DG, Smeltzer MS, Alam MA.

Bioorg Med Chem Lett. 2018 Sep 15;28(17):2914-2919. doi: 10.1016/j.bmcl.2018.07.016. Epub 2018 Jul 10.

5.

Local Delivery of Amikacin and Vancomycin from Chitosan Sponges Prevent Polymicrobial Implant-Associated Biofilm.

Boles LR, Awais R, Beenken KE, Smeltzer MS, Haggard WO, Jessica AJ.

Mil Med. 2018 Mar 1;183(suppl_1):459-465. doi: 10.1093/milmed/usx161.

PMID:
29635622
6.

Ciprofloxacin and Rifampin Dual Antibiotic-Loaded Biopolymer Chitosan Sponge for Bacterial Inhibition.

Wells CM, Beenken KE, Smeltzer MS, Courtney HS, Jennings JA, Haggard WO.

Mil Med. 2018 Mar 1;183(suppl_1):433-444. doi: 10.1093/milmed/usx150.

PMID:
29635619
7.

Introduction to the special issue on thermal therapy and infectious diseases.

Chopra R, Levi-Polyachenko N, Smeltzer MS.

Int J Hyperthermia. 2018 Mar;34(2):133-134. doi: 10.1080/02656736.2018.1424947. No abstract available.

PMID:
29498313
8.

Novel Linear Lipopeptide Paenipeptins with Potential for Eradicating Biofilms and Sensitizing Gram-Negative Bacteria to Rifampicin and Clarithromycin.

Moon SH, Zhang X, Zheng G, Meeker DG, Smeltzer MS, Huang E.

J Med Chem. 2017 Dec 14;60(23):9630-9640. doi: 10.1021/acs.jmedchem.7b01064. Epub 2017 Nov 22.

PMID:
29136469
9.

Versatility of targeted antibiotic-loaded gold nanoconstructs for the treatment of biofilm-associated bacterial infections.

Meeker DG, Wang T, Harrington WN, Zharov VP, Johnson SA, Jenkins SV, Oyibo SE, Walker CM, Mills WB, Shirtliff ME, Beenken KE, Chen J, Smeltzer MS.

Int J Hyperthermia. 2018 Mar;34(2):209-219. doi: 10.1080/02656736.2017.1392047.

10.

Impact of Staphylococcus aureus regulatory mutations that modulate biofilm formation in the USA300 strain LAC on virulence in a murine bacteremia model.

Rom JS, Atwood DN, Beenken KE, Meeker DG, Loughran AJ, Spencer HJ, Lantz TL, Smeltzer MS.

Virulence. 2017 Nov 17;8(8):1776-1790. doi: 10.1080/21505594.2017.1373926. Epub 2017 Oct 4.

11.

Evaluation of a chitosan-polyethylene glycol paste as a local antibiotic delivery device.

Rhodes CS, Alexander CM, Berretta JM, Courtney HS, Beenken KE, Smeltzer MS, Bumgardner JD, Haggard WO, Jennings JA.

World J Orthop. 2017 Feb 18;8(2):130-141. doi: 10.5312/wjo.v8.i2.130. eCollection 2017 Feb 18.

12.

Blended Chitosan Paste for Infection Prevention: Preliminary and Preclinical Evaluations.

Berretta JM, Jennings JA, Courtney HS, Beenken KE, Smeltzer MS, Haggard WO.

Clin Orthop Relat Res. 2017 Jul;475(7):1857-1870. doi: 10.1007/s11999-017-5231-y.

13.

Phosphatidylcholine Coatings Deliver Local Antimicrobials and Reduce Infection in a Murine Model: A Preliminary Study.

Harris MA, Beenken KE, Smeltzer MS, Haggard WO, Jennings JA.

Clin Orthop Relat Res. 2017 Jul;475(7):1847-1853. doi: 10.1007/s11999-016-5211-7.

14.

Antibiotic-loaded phosphatidylcholine inhibits staphylococcal bone infection.

Jennings JA, Beenken KE, Skinner RA, Meeker DG, Smeltzer MS, Haggard WO, Troxel KS.

World J Orthop. 2016 Aug 18;7(8):467-74. doi: 10.5312/wjo.v7.i8.467. eCollection 2016 Aug 18.

15.

Could targeted, antibiotic-loaded gold nanoconstructs be a new magic bullet to fight infection?

Meeker DG, Chen J, Smeltzer MS.

Nanomedicine (Lond). 2016 Sep;11(18):2379-82. doi: 10.2217/nnm-2016-0260. Epub 2016 Aug 16. No abstract available.

16.

Staphylococcus aureus Pathogenesis: The Importance of Reduced Cytotoxicity.

Smeltzer MS.

Trends Microbiol. 2016 Sep;24(9):681-682. doi: 10.1016/j.tim.2016.07.003. Epub 2016 Jul 19.

PMID:
27450110
17.

Synergistic Photothermal and Antibiotic Killing of Biofilm-Associated Staphylococcus aureus Using Targeted Antibiotic-Loaded Gold Nanoconstructs.

Meeker DG, Jenkins SV, Miller EK, Beenken KE, Loughran AJ, Powless A, Muldoon TJ, Galanzha EI, Zharov VP, Smeltzer MS, Chen J.

ACS Infect Dis. 2016 Apr 8;2(4):241-250. Epub 2016 Feb 10.

18.

Evaluation of Antibiotics Active against Methicillin-Resistant Staphylococcus aureus Based on Activity in an Established Biofilm.

Meeker DG, Beenken KE, Mills WB, Loughran AJ, Spencer HJ, Lynn WB, Smeltzer MS.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5688-94. doi: 10.1128/AAC.01251-16. Print 2016 Oct.

19.

Impact of sarA and Phenol-Soluble Modulins on the Pathogenesis of Osteomyelitis in Diverse Clinical Isolates of Staphylococcus aureus.

Loughran AJ, Gaddy D, Beenken KE, Meeker DG, Morello R, Zhao H, Byrum SD, Tackett AJ, Cassat JE, Smeltzer MS.

Infect Immun. 2016 Aug 19;84(9):2586-94. doi: 10.1128/IAI.00152-16. Print 2016 Sep.

20.

Corrigendum to "Sesquiterpene lactones from Gynoxys verrucosa and their anti-MRSA activity" [J. Ethnopharmacol. 137 (2011) 1055-1059].

Ordóñez PE, Quave CL, Reynolds WF, Varughese KI, Berry B, Breen PJ, Malagón O, Vidari G, Smeltzer MS, Compadre CM.

J Ethnopharmacol. 2016 Jun 20;186:392. doi: 10.1016/j.jep.2016.04.022. Epub 2016 May 8. No abstract available.

PMID:
27165010
21.

XerC Contributes to Diverse Forms of Staphylococcus aureus Infection via agr-Dependent and agr-Independent Pathways.

Atwood DN, Beenken KE, Loughran AJ, Meeker DG, Lantz TL, Graham JW, Spencer HJ, Smeltzer MS.

Infect Immun. 2016 Mar 24;84(4):1214-1225. doi: 10.1128/IAI.01462-15. Print 2016 Apr.

22.

Regulatory Mutations Impacting Antibiotic Susceptibility in an Established Staphylococcus aureus Biofilm.

Atwood DN, Beenken KE, Lantz TL, Meeker DG, Lynn WB, Mills WB, Spencer HJ, Smeltzer MS.

Antimicrob Agents Chemother. 2016 Jan 11;60(3):1826-9. doi: 10.1128/AAC.02750-15.

23.

Polymicrobial Biofilm Inhibition Effects of Acetate-Buffered Chitosan Sponge Delivery Device.

Jennings JA, Beenken KE, Parker AC, Smith JK, Courtney HS, Smeltzer MS, Haggard WO.

Macromol Biosci. 2016 Apr;16(4):591-8. doi: 10.1002/mabi.201500347. Epub 2016 Jan 12.

PMID:
26756211
24.

Novel Bone-Targeting Agent for Enhanced Delivery of Vancomycin to Bone.

Albayati ZA, Sunkara M, Schmidt-Malan SM, Karau MJ, Morris AJ, Steckelberg JM, Patel R, Breen PJ, Smeltzer MS, Taylor KG, Merten KE, Pierce WM, Crooks PA.

Antimicrob Agents Chemother. 2015 Dec 14;60(3):1865-8. doi: 10.1128/AAC.01609-15.

25.

SaeRS-dependent inhibition of biofilm formation in Staphylococcus aureus Newman.

Cue D, Junecko JM, Lei MG, Blevins JS, Smeltzer MS, Lee CY.

PLoS One. 2015 Apr 8;10(4):e0123027. doi: 10.1371/journal.pone.0123027. eCollection 2015.

26.

Comparative impact of diverse regulatory loci on Staphylococcus aureus biofilm formation.

Atwood DN, Loughran AJ, Courtney AP, Anthony AC, Meeker DG, Spencer HJ, Gupta RK, Lee CY, Beenken KE, Smeltzer MS.

Microbiologyopen. 2015 Jun;4(3):436-51. doi: 10.1002/mbo3.250. Epub 2015 Mar 21.

27.

Novel Antibiotic-loaded Point-of-care Implant Coating Inhibits Biofilm.

Jennings JA, Carpenter DP, Troxel KS, Beenken KE, Smeltzer MS, Courtney HS, Haggard WO.

Clin Orthop Relat Res. 2015 Jul;473(7):2270-82. doi: 10.1007/s11999-014-4130-8.

28.

Characterization of local delivery with amphotericin B and vancomycin from modified chitosan sponges and functional biofilm prevention evaluation.

Parker AC, Beenken KE, Jennings JA, Hittle L, Shirtliff ME, Bumgardner JD, Smeltzer MS, Haggard WO.

J Orthop Res. 2015 Mar;33(3):439-47. doi: 10.1002/jor.22760. Epub 2014 Nov 20.

29.

Impact of individual extracellular proteases on Staphylococcus aureus biofilm formation in diverse clinical isolates and their isogenic sarA mutants.

Loughran AJ, Atwood DN, Anthony AC, Harik NS, Spencer HJ, Beenken KE, Smeltzer MS.

Microbiologyopen. 2014 Dec;3(6):897-909. doi: 10.1002/mbo3.214. Epub 2014 Sep 25.

30.

Chitosan coating to enhance the therapeutic efficacy of calcium sulfate-based antibiotic therapy in the treatment of chronic osteomyelitis.

Beenken KE, Smith JK, Skinner RA, Mclaren SG, Bellamy W, Gruenwald MJ, Spencer HJ, Jennings JA, Haggard WO, Smeltzer MS.

J Biomater Appl. 2014 Oct;29(4):514-23. doi: 10.1177/0885328214535452. Epub 2014 May 21.

31.

Impact of the functional status of saeRS on in vivo phenotypes of Staphylococcus aureus sarA mutants.

Beenken KE, Mrak LN, Zielinska AK, Atwood DN, Loughran AJ, Griffin LM, Matthews KA, Anthony AM, Spencer HJ, Skinner RA, Post GR, Lee CY, Smeltzer MS.

Mol Microbiol. 2014 Jun;92(6):1299-312. doi: 10.1111/mmi.12629. Epub 2014 May 12.

32.

Investigation of biofilm formation in clinical isolates of Staphylococcus aureus.

Cassat JE, Smeltzer MS, Lee CY.

Methods Mol Biol. 2014;1085:195-211. doi: 10.1007/978-1-62703-664-1_12.

PMID:
24085698
33.

A secreted bacterial protease tailors the Staphylococcus aureus virulence repertoire to modulate bone remodeling during osteomyelitis.

Cassat JE, Hammer ND, Campbell JP, Benson MA, Perrien DS, Mrak LN, Smeltzer MS, Torres VJ, Skaar EP.

Cell Host Microbe. 2013 Jun 12;13(6):759-72. doi: 10.1016/j.chom.2013.05.003.

34.

Photoacoustic and photothermal detection of circulating tumor cells, bacteria and nanoparticles in cerebrospinal fluid in vivo and ex vivo.

Nedosekin DA, Juratli MA, Sarimollaoglu M, Moore CL, Rusch NJ, Smeltzer MS, Zharov VP, Galanzha EI.

J Biophotonics. 2013 Jun;6(6-7):523-33. doi: 10.1002/jbio.201200242. Epub 2013 May 16.

35.

Hyaluronidase expression and biofilm involvement in Staphylococcus aureus UAMS-1 and its sarA, agr and sarA agr regulatory mutants.

Hart ME, Tsang LH, Deck J, Daily ST, Jones RC, Liu H, Hu H, Hart MJ, Smeltzer MS.

Microbiology. 2013 Apr;159(Pt 4):782-91. doi: 10.1099/mic.0.065367-0. Epub 2013 Feb 7.

36.

Quercus cerris extracts limit Staphylococcus aureus biofilm formation.

Hobby GH, Quave CL, Nelson K, Compadre CM, Beenken KE, Smeltzer MS.

J Ethnopharmacol. 2012 Dec 18;144(3):812-5. doi: 10.1016/j.jep.2012.10.042. Epub 2012 Nov 2.

37.

sarA-mediated repression of protease production plays a key role in the pathogenesis of Staphylococcus aureus USA300 isolates.

Zielinska AK, Beenken KE, Mrak LN, Spencer HJ, Post GR, Skinner RA, Tackett AJ, Horswill AR, Smeltzer MS.

Mol Microbiol. 2012 Dec;86(5):1183-96. doi: 10.1111/mmi.12048. Epub 2012 Oct 17.

38.

In vivo magnetic enrichment, photoacoustic diagnosis, and photothermal purging of infected blood using multifunctional gold and magnetic nanoparticles.

Galanzha EI, Shashkov E, Sarimollaoglu M, Beenken KE, Basnakian AG, Shirtliff ME, Kim JW, Smeltzer MS, Zharov VP.

PLoS One. 2012;7(9):e45557. doi: 10.1371/journal.pone.0045557. Epub 2012 Sep 26.

39.

Use of xylitol to enhance the therapeutic efficacy of polymethylmethacrylate-based antibiotic therapy in treatment of chronic osteomyelitis.

Beenken KE, Bradney L, Bellamy W, Skinner RA, McLaren SG, Gruenwald MJ, Spencer HJ, Smith JK, Haggard WO, Smeltzer MS.

Antimicrob Agents Chemother. 2012 Nov;56(11):5839-44. doi: 10.1128/AAC.01127-12. Epub 2012 Sep 4.

40.

The staphylococcal accessory regulator, SarA, is an RNA-binding protein that modulates the mRNA turnover properties of late-exponential and stationary phase Staphylococcus aureus cells.

Morrison JM, Anderson KL, Beenken KE, Smeltzer MS, Dunman PM.

Front Cell Infect Microbiol. 2012 Mar 8;2:26. doi: 10.3389/fcimb.2012.00026. eCollection 2012.

41.

Evaluation of dynamic [18F]-FDG-PET imaging for the detection of acute post-surgical bone infection.

Brown TL, Spencer HJ, Beenken KE, Alpe TL, Bartel TB, Bellamy W, Gruenwald JM, Skinner RA, McLaren SG, Smeltzer MS.

PLoS One. 2012;7(7):e41863. doi: 10.1371/journal.pone.0041863. Epub 2012 Jul 30.

42.

Biofilm-infected intracerebroventricular shunts elicit inflammation within the central nervous system.

Snowden JN, Beaver M, Smeltzer MS, Kielian T.

Infect Immun. 2012 Sep;80(9):3206-14. doi: 10.1128/IAI.00645-12. Epub 2012 Jul 2.

43.

saeRS and sarA act synergistically to repress protease production and promote biofilm formation in Staphylococcus aureus.

Mrak LN, Zielinska AK, Beenken KE, Mrak IN, Atwood DN, Griffin LM, Lee CY, Smeltzer MS.

PLoS One. 2012;7(6):e38453. doi: 10.1371/journal.pone.0038453. Epub 2012 Jun 7.

44.

Impact of extracellular nuclease production on the biofilm phenotype of Staphylococcus aureus under in vitro and in vivo conditions.

Beenken KE, Spencer H, Griffin LM, Smeltzer MS.

Infect Immun. 2012 May;80(5):1634-8. doi: 10.1128/IAI.06134-11. Epub 2012 Feb 21.

45.

Ellagic acid derivatives from Rubus ulmifolius inhibit Staphylococcus aureus biofilm formation and improve response to antibiotics.

Quave CL, Estévez-Carmona M, Compadre CM, Hobby G, Hendrickson H, Beenken KE, Smeltzer MS.

PLoS One. 2012;7(1):e28737. doi: 10.1371/journal.pone.0028737. Epub 2012 Jan 5.

46.

Nuclease modulates biofilm formation in community-associated methicillin-resistant Staphylococcus aureus.

Kiedrowski MR, Kavanaugh JS, Malone CL, Mootz JM, Voyich JM, Smeltzer MS, Bayles KW, Horswill AR.

PLoS One. 2011;6(11):e26714. doi: 10.1371/journal.pone.0026714. Epub 2011 Nov 11.

47.

Sesquiterpene lactones from Gynoxys verrucosa and their anti-MRSA activity.

Ordóñez PE, Quave CL, Reynolds WF, Varughese KI, Berry B, Breen PJ, Malagón O, Vidari G, Smeltzer MS, Compadre CM.

J Ethnopharmacol. 2011 Sep 2;137(2):1055-9. doi: 10.1016/j.jep.2011.07.012. Epub 2011 Jul 12. Erratum in: J Ethnopharmacol. 2016 Jun 20;186:392. Vidari G [added].

48.

Staphylococcus aureus evades the extracellular antimicrobial activity of mast cells by promoting its own uptake.

Abel J, Goldmann O, Ziegler C, Höltje C, Smeltzer MS, Cheung AL, Bruhn D, Rohde M, Medina E.

J Innate Immun. 2011;3(5):495-507. doi: 10.1159/000327714. Epub 2011 Jun 8.

49.

Development of a novel, highly quantitative in vivo model for the study of biofilm-impaired cutaneous wound healing.

Gurjala AN, Geringer MR, Seth AK, Hong SJ, Smeltzer MS, Galiano RD, Leung KP, Mustoe TA.

Wound Repair Regen. 2011 May-Jun;19(3):400-10. doi: 10.1111/j.1524-475X.2011.00690.x. Epub 2011 Apr 21.

PMID:
21518094
50.

Defining the strain-dependent impact of the Staphylococcal accessory regulator (sarA) on the alpha-toxin phenotype of Staphylococcus aureus.

Zielinska AK, Beenken KE, Joo HS, Mrak LN, Griffin LM, Luong TT, Lee CY, Otto M, Shaw LN, Smeltzer MS.

J Bacteriol. 2011 Jun;193(12):2948-58. doi: 10.1128/JB.01517-10. Epub 2011 Apr 8.

Supplemental Content

Loading ...
Support Center